BamSEC and AlphaSense Join Forces
Learn More

Viridian Therapeutics Inc.

NASDAQ: VRDN    
Share price (11/21/24): $19.62    
Market cap (11/21/24): $1.554 billion
Search in Documents
Key Exhibits
External Links

Underwriting Agreements Filter

EX-1.1
from 8-K 47 pages 10,666,600 Shares of Common Stock 20,000 Shares of Series B Preferred Stock Viridian Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1.1
from 8-K 45 pages 7,142,858 Shares of Common Stock Viridian Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1.2
from S-3ASR 30 pages Open Market Sale Agreementsm
12/34/56
EX-1.1
from 8-K 46 pages 9,627,640 Shares of Common Stock 28,084 Shares of Series B Preferred Stock Viridian Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1.2
from S-3 40 pages Open Market Sale Agreementsm
12/34/56
EX-1.1
from 8-K 38 pages 6,185,454 Shares of Common Stock 23,126 Shares of Series B Preferred Stock Viridian Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1.1
from 8-K 42 pages Open Market Sale Agreementsm
12/34/56
EX-1
from SC 13G 1 page Agreement
12/34/56
EX-1.1
from 8-K 43 pages 15,000,000 Shares of Common Stock and Warrants to Purchase 7,500,000 Shares of Common Stock Miragen Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1.1
from 8-K 42 pages 7,000,000 Miragen Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1.2
from S-3 41 pages Signal Genetics Inc. Shares of Common Stock (Par Value $0.01 Per Share) Controlled Equity Offeringsm Sales Agreement
12/34/56
EX-1.1
from S-1/A 43 pages Underwriting Agreement Between Signal Genetics, Inc. and Aegis Capital Corp., as Representative of the Several Underwriters Signal Genetics, Inc. Underwriting Agreement
12/34/56
EX-1.1
from S-1 44 pages Underwriting Agreement Between Signal Genetics, Inc. and Aegis Capital Corp., as Representative of the Several Underwriters Signal Genetics, Inc. Underwriting Agreement
12/34/56